Showing posts with label Precigenetics. Show all posts
Showing posts with label Precigenetics. Show all posts

Wednesday, May 20, 2026

Top Minds In Tech Give Us Manipulated Videos (Satire)



 



Top Minds In Tech Give Us Manipulated Videos

Humanity’s Brightest Engineers Finally Solve The Problem Of Authentic Footage

Once upon a time, the internet gave us cat videos.

A cat falling off a couch.

A cat afraid of cucumbers.

A cat staring into the void like a middle manager during quarterly planning.

It was beautiful. Honest. Democratic. Civilization at its peak.

Then the top minds in technology arrived and said:

“What if none of this were real?”

Today, humanity possesses the greatest concentration of intelligence, capital, and compute power in recorded history. Thousands of GPUs hum day and night consuming enough electricity to power medium-sized nations.

And what are the brightest people doing with this power?

Manipulating videos.

That’s it.

That’s the revolution.

For decades science fiction promised flying cars, immortality, moon colonies, and robot assistants that would finally understand calendar scheduling.

Instead, 2026 gave us:
“Watch this historically accurate video of Napoleon livestreaming his skincare routine.”

The world’s greatest engineering talent has united around one mission:
making fake videos slightly more fake.

Sundar Pichai wakes up every morning asking:
“How can we make a video of a hamster podcast look even more cinematic?”

Elon Musk is building enough compute to simulate entire civilizations, apparently so somebody can generate a deepfake of Abraham Lincoln reviewing protein powder.

Sam Altman speaks solemnly about the future of humanity while millions of people use frontier AI systems to create videos of penguins running hedge funds.

This is what happened to the civilization that invented penicillin.

The pitch decks are extraordinary.

“Foundational Multimodal Reality Synthesis Infrastructure.”

Translation:
“We made fake videos faster.”

“Universal Video Generation Platform.”

Translation:
“The Pope can now breakdance.”

“Context-Aware Temporal World Models.”

Translation:
“Here’s Batman eating tacos in Mumbai.”

Investors nod seriously while pretending this is the Manhattan Project.

Entire conferences now exist where billionaire founders stand on stage showing increasingly realistic fake humans blinking naturally.

The audience erupts in applause.

“INCREDIBLE.”

“THE FUTURE.”

“THE EYELID MOVEMENT IS SO REALISTIC.”

Meanwhile, somewhere in America, an actual doctor is still faxing patient records.

You would think with all this AI, all this compute, all these agents that don’t unionize — not yet! — somebody would focus on curing cancer.

But no.

Humanity looked at the sum total of scientific progress and concluded the highest priority was:
“Generate a photorealistic Viking influencer explaining crypto.”

Imagine explaining this to scientists from previous centuries.

Isaac Newton:
“You harnessed unimaginable computational power? Surely you solved physics?”

“No, sir. We generated fake reaction videos.”

Marie Curie:
“You mapped the atom?”

“Yes, and now we can create an AI video of a raccoon teaching yoga.”

The scientists quietly return to the grave.

The funniest part is the moral seriousness surrounding all this.

Every AI launch video sounds like civilization itself hangs in the balance.

Dramatic music.

Slow-motion shots of servers.

Founders staring thoughtfully into the middle distance like generals before battle.

Then the product demo appears:
“A squirrel doing stand-up comedy.”

Humanity has mistaken GPU clusters for destiny.

And the arms race is escalating.

One company releases 8-second AI video clips.

Another releases 60-second clips.

A third announces:
“Our videos now contain emotionally coherent lighting transitions.”

Wall Street cheers wildly.

At this rate, by 2032, AI will generate entire fake Oscar-winning films while actual screenwriters live inside converted storage units.

Meanwhile the internet becomes unusable.

Every video online carries the emotional energy of a dream you had during a fever.

Was that politician real?

Was that celebrity apology real?

Did that panda actually drive a forklift through a Walmart?

Nobody knows anymore.

Truth itself now comes with buffering issues.

And yet — amid this festival of synthetic nonsense — there are still a few people trying to use technology for things that might actually matter.

Like curing diseases.

Like understanding biology.

Like extending human life instead of merely extending the runtime of fake medieval TikToks.

Which brings us to Parmita Mishra.

While Silicon Valley’s emperors compete to see who can generate the most realistic fake footage of astronauts playing saxophone underwater, Parmita Mishra is apparently busy trying to cure cancer.

Which increasingly feels like a radical act.

Imagine showing up to a venture capital meeting today and saying:

“We use AI to understand disease pathways and accelerate drug discovery.”

Investors would stare blankly.

“But where is the manipulated raccoon content?”

“No viral deepfake strategy?”

“Can the cancer cells at least dance?”

The tragedy of modern tech is not that humanity lacks intelligence.

It is that civilization’s smartest people keep getting distracted by shiny objects with excellent rendering quality.

We built machines capable of accelerating biology, chemistry, medicine, materials science, and energy discovery.

And the first thing we asked them to do was:
“Make me look taller in video calls.”

This may be the defining comedy of the age.

The Industrial Revolution gave us railroads.

The Space Age gave us moon landings.

The AI Age gave us:
“Hyperrealistic fake podcast clips of philosophers who never existed.”

Somewhere tonight, thousands of elite engineers are optimizing diffusion models so an AI-generated koala can properly maintain visual consistency across frames.

And somewhere else, a scientist is trying to save millions of lives with a fraction of the funding and one-tenth the attention span from the internet.

History may eventually decide who the real top minds were.




at No comments:
Labels: , , , ,

Monday, May 18, 2026

PreciGenetics: The Grand Solara Vision

Himalayan Compute: Podcasts

Book: Cell Cinema Revolution
Book: PreciGenetics: The Technology That Lets Us Watch Life Think: How Photons, Cells, and AI May Help Us Cure Cancer and Rewrite Medicine
Book: Himalayan Compute: Grand Solara Vision

 


PreciGenetics: The Grand Solara Vision

A 10–15 Year Roadmap to a Trillion-Dollar Valuation

“Making Biology Legible. Making Disease Optional.”

PreciGenetics is not building another biotech company. It is building the missing infrastructure layer of modern medicine: the ability to continuously observe living cellular behavior in real time, and convert that into computable data. As described in the two books, this is the transition from biology as “snapshots” to biology as “movies”—a shift that turns medicine from guesswork into engineering. 

The long-term thesis is simple:

Whoever owns the evidence layer owns the future of medicine.

PreciGenetics becomes a trillion-dollar company by becoming the AWS + Google Maps + Bloomberg Terminal of biology:

  • AWS = scalable compute infrastructure for biology

  • Google Maps = navigation through cellular state space

  • Bloomberg = continuous real-time signals for decision-making

And the platform at the center is COMPASS: a photonic-AI system that watches cells without touching them.

The Big Picture: Why This Can Become a $1T Company

Biotech today is constrained not by lack of ideas, but by lack of proof. AI is generating molecules faster than the world can validate them. That creates a new bottleneck: validation.

PreciGenetics sits exactly at that bottleneck.

This is not “one more drug discovery company.”
This is the company that makes drug discovery compound like software.

The two books frame it clearly:

  • Biology becomes computable

  • Experiments become continuous learning

  • Evidence becomes the moat

  • Closed-loop biology becomes the real AGI of medicine

That is trillion-dollar territory.

The Fundraising Narrative (The UAE Sovereign Wealth Fund Pitch)

Round: $200M at $1B valuation (2026–2027)

This round is framed as a strategic steal because it buys the fund exposure to what becomes the dominant infrastructure layer of medicine.

But the key is: PreciGenetics is compute-constrained.

The platform is GPU-intensive, because the entire vision depends on building high-dimensional trajectories and training models on cellular movies.

Compute is the bottleneck. So PreciGenetics solves it permanently.

Action:
PreciGenetics allocates $100M as a down payment into Himalayan Compute, securing the cheapest compute in the world at half price.

This transforms PreciGenetics from:

  • a promising platform company

into:

  • a platform company with effectively unlimited scale economics.

Compute becomes not a cost center, but a strategic weapon.

That is what allows PreciGenetics to rapidly win mega customers.

Why the $200M Raise is a “Steal”

Because this is the moment where the company transitions from:

  • building the microscope

to:

  • selling the microscope + the evidence engine + the closed-loop biology stack.

And once pharma sees validation speed increase, procurement budgets explode.

Pharma will pay almost anything to reduce late-stage failure risk.

The two books emphasize that “moving truth earlier” is the single most valuable wedge.

That means revenues scale extremely fast.

The Grand Solara Roadmap (10–15 Years)

Phase 1 (Years 1–3): “Build the Evidence Machine”

Goal: Prove COMPASS as the definitive readout layer

Core Deliverables

  • COMPASS v1 deployed in elite labs

  • High-confidence trajectory datasets (toxicity, resistance, adaptation)

  • Demonstrated repeatability across cell types and conditions

  • Model training pipelines optimized on Himalayan Compute

Commercial Strategy

  • Start with “derisking” as the wedge market

  • Sell to pharma as a platform subscription + per-experiment fee

Why this works
Derisking is the easiest purchase decision: pharma already knows toxicity and late-stage failure is killing them.

Revenue Target

  • $50M–$150M ARR by end of Phase 1

Valuation Target

  • $5B–$15B

Phase 2 (Years 3–6): “The Pharma Lock-In Era”

Goal: Become the default validation engine for global pharma

This is when PreciGenetics becomes “mandatory infrastructure.”

Product Expansion

  • Automated experiment loops

  • AI-guided perturbation design

  • Predictive phenotype modeling

  • Standardized “Cell Cinema Reports” for regulators

Business Model Shift
PreciGenetics transitions from being a tool vendor to being a platform utility.

It becomes embedded into:

  • discovery

  • tox

  • IND preparation

  • biomarker validation

  • clinical strategy design

Mega Customer Strategy
Target: Top 30 pharma + top 200 biotechs.
If even 10 of them integrate deeply, revenues explode.

Revenue Target

  • $500M–$1B ARR

Valuation Target

  • $30B–$80B

Phase 3 (Years 6–9): “The Living Cell Atlas Era”

Goal: Build the world’s first Living Cell Atlas

The books frame this explicitly: a database not of cell identity, but of cell destiny—“where is this cell going?”

This is the Google Maps moment of biology.

Atlas Features

  • Resistance trajectory library

  • Toxicity trajectory library

  • Adaptive response fingerprinting

  • Drug response prediction before dosing

Platform Flywheel
More customers → more experiments → more trajectories → better models → more customers.

This becomes a compounding data monopoly.

Revenue Target

  • $3B–$8B ARR

Valuation Target

  • $150B–$300B

Phase 4 (Years 9–12): “Closed-Loop Biology Becomes Standard”

Goal: Transform drug discovery into continuous learning

At this stage, PreciGenetics is no longer a “measurement platform.”
It becomes the operating system of drug development.

The books describe closed-loop biology as the real AGI of medicine: experiment + model coupling that improves continuously.

New Capabilities

  • Autonomous experiment planning

  • Adaptive therapy simulation

  • AI-designed perturbations validated instantly

  • “Navigation through cellular state space”

Industry Impact
Pharma pipelines reorganize around PreciGenetics data.

Revenue Target

  • $10B–$25B ARR

Valuation Target

  • $400B–$700B

Phase 5 (Years 12–15): “The Trillion-Dollar Infrastructure Layer”

Goal: Become the global evidence authority for biology

This is the final transformation:

PreciGenetics becomes the “FDA-before-the-FDA” for biological truth.

It owns:

  • the largest living dataset ever assembled

  • the dominant trajectory models

  • the validation workflow standard

  • the biological evidence API layer

Massive Expansion Markets

  • cancer treatment prediction

  • longevity interventions

  • autoimmune disease modeling

  • neurodegenerative progression mapping

  • infectious disease adaptation modeling

  • personalized treatment simulations

At this point, medicine becomes engineering.

Revenue Target

  • $40B–$80B ARR

Valuation Target

  • $1T+

The Himalayan Compute Strategy: Turning Compute Into a Moat

Most biotech platforms die because they cannot afford scale.

PreciGenetics does the opposite:

  • It locks in the world’s cheapest compute

  • It buys the future capacity early

  • It becomes the only platform able to train continuously at planetary scale

This is like Amazon buying electricity generation before building AWS.

This is the genius of the $100M down payment.

Compute is not an expense.
Compute is the factory.

And PreciGenetics becomes the Ford of biological evidence.

The UAE Sovereign Wealth Fund Strategic Fit

This deal is not just an investment. It is a national strategic asset.

A UAE sovereign wealth fund gains:

  • Ownership in the next trillion-dollar healthcare infrastructure layer

  • A future anchor of biotech R&D inside UAE

  • AI + compute + biotech convergence leadership

  • Potential to create a “Dubai of Medicine” global hub

The UAE can position itself as the neutral global capital of:

  • cancer prediction

  • drug validation

  • clinical acceleration

  • longevity research infrastructure

Why Revenues Will Scale Faster Than People Expect

Once pharma sees proof that PreciGenetics reduces late-stage failures, budgets will shift massively.

Because late-stage failures are not “losses.”
They are multi-billion-dollar catastrophes.

PreciGenetics sells the one product pharma wants most:

certainty.

And the books explicitly make that argument: lowering uncertainty changes the behavior of the entire industry.

That is why this becomes not a $10B company, but a civilization-scale platform.  

The Grand Solara Thesis (One Sentence)

PreciGenetics will become a trillion-dollar company by turning biology into a readable, computable, continuously monitored system—so that medicine compounds like software and disease becomes optional.

The 3-Line Investor Closing Argument

  1. AI will generate infinite drug candidates. Validation is the bottleneck.

  2. PreciGenetics is the validation engine: Cell Cinema + COMPASS + Living Cell Atlas.

  3. With Himalayan Compute locked in at half price, PreciGenetics scales faster and cheaper than any competitor.

Therefore: $200M at $1B is not expensive. It is underpriced.

This is the rare moment where a sovereign fund can buy into the future before Wall Street understands what is happening.



at No comments:
Labels:

Wednesday, May 13, 2026

PreciGenetics: Too Big For VC

it is actually absurd how category-defining precigenetics is. biosensing+AI a barren land. we make sensors for cells, that puts us in a position to distribute sensors across pharma, including manufacturing one day.

investors need to read about exactly why, because this is life-saving value-creation. my entire X account was created to bridge the 'unsexy' biotech/pharma world and silicon valley.

if i had 1B in funding today, we would take over so fast, but we will build our way to it.

our IP is translational. we aren't early, we are just in time. people are early in understanding the kind of value we are creating using hardcore engineering. the only companies who are interested in this are in Germany, and they have a lot of hardware tech debt.

biosensing isn't just a data-generation machine. it is an URGENT need in manufacturing. there's single-digit number of professors who understand the field of label-free cell biophotonics and we take their advice every step of the way.

CAR T-cell production typically costs between ($170,000) and ($220,000) per patient in direct manufacturing, logistics, and quality control expenses. half a million per infusion

cell Tx is growing at the highest CAGR is all of biotech/pharma.

just one example of how our biosensing is going to not just create drugs but also cut costs.


PreciGenetics Is Too Big for Venture Capital: The Case for Strategic Mega-Customers Like NASA for SpaceX.
PreciGenetics is building Cell Cinema — a photonic-AI platform that delivers real-time chemical movies of living cells in motion, without labels or destruction. This turns biology from forensic snapshots (kill the cell, stain it, sequence the corpse) into continuous, predictive observation. It addresses core bottlenecks in drug discovery, cell therapy manufacturing, and precision medicine by generating rich, dynamic data that AI can actually use.
Founder and CEO Parmita Mishra has highlighted the absurdity of how category-defining this is in a barren biosensing + AI landscape. Their sensors for cells position the company to distribute across pharma, including manufacturing. One example: CAR-T production costs $170k–$220k per patient in direct manufacturing, logistics, and QC, with total costs around half a million per infusion. Real-time biosensing can slash failure rates and costs in the fastest-growing segment of biotech.
This is not a modest SaaS or incremental tool play. It is foundational infrastructure for the next era of biology — digitizing living systems at scale, much like how compute and sensors transformed other industries. With such ambition, PreciGenetics is too big for traditional VC. Why VC Is the Wrong FitVenture capital excels at early product-market fit, team building, and scaling software-like businesses with clear 3–7 year exits. PreciGenetics operates at hardware-photonics-biology-AI intersection with long development cycles, regulatory considerations, and capital intensity that dwarf typical seed/Series A expectations. Their IP is translational and "just in time," but market understanding lags, especially outside specialized pockets (e.g., German hardware players with tech debt).
Raising enough to move at the necessary speed via VC would mean heavy dilution, pressure for premature pivots, or incrementalism. SpaceX provides the clearest analogy: Elon Musk's venture had effectively zero traditional VC backers in its formative stages for the core vision. Instead, NASA showed up as a customer with massive contracts (billions in development and launch services), providing both capital and validation.
This de-risked the technology, proved reliability, and unlocked the broader market. PreciGenetics needs analogous strategic customers who pay for the platform because it solves existential problems in their workflows — not equity investors betting on a future liquidity event.
Government agencies, large pharma, biotech giants, and specialized manufacturers can write nine- and ten-figure checks for tools that accelerate discovery, cut manufacturing costs, improve yields, and de-risk billion-dollar pipelines. PreciGenetics' real-time, non-destructive cellular insights offer precisely that leverage.10 Potential Customers That Could Collectively Deliver ~$100M+Here is a realistic list of 10 entities (or categories) that could become major customers. Together, through platform sales, service contracts, co-development deals, manufacturing integration, or large-scale data/insight subscriptions, they could channel $100M+ in revenue or equivalent non-dilutive funding over the next few years as the technology matures:
  1. Major Pharma Giants (e.g., Pfizer, Roche, Novartis, Merck) — Multi-year platform deployments for high-throughput drug screening and mechanism-of-action studies. Real-time trajectory prediction could compress decision cycles from weeks to hours and reduce late-stage failures.
  2. Cell & Gene Therapy Leaders (e.g., Gilead/Kite, Bristol Myers Squibb, bluebird bio) — Integration into CAR-T and other autologous cell therapy manufacturing for real-time QC, process monitoring, and yield optimization. Given per-patient costs, even modest improvements justify big contracts.
  3. Contract Development & Manufacturing Organizations (CDMOs like Lonza, WuXi, Catalent) — Biosensing as a service layer for client manufacturing runs, especially in cell therapy and biologics where process analytical technology (PAT) is a regulatory and efficiency priority.
  4. U.S. Government Biomedical Research (NIH, BARDA, ARPA-H) — Large grants or contracts for foundational research tools, pandemic preparedness platforms, or advanced manufacturing. ARPA-H's focus on high-risk, high-reward biotech aligns perfectly.
  5. FDA or Equivalent Regulatory Bodies (or pharma consortia working with them) — Collaborative programs to validate next-gen analytics for faster approvals and better safety monitoring.
  6. Large Cancer Research Centers & Hospitals (e.g., MD Anderson, Memorial Sloan Kettering, or international equivalents) — Precision oncology applications, patient-derived organoid/ cell monitoring, and personalized therapy development.
  7. Agri-Biotech & Synthetic Biology Companies (e.g., Corteva, Ginkgo Bioworks, or industrial biotech players) — Extending cell cinema to microbial or plant cells for strain engineering, biomanufacturing optimization, and sustainable chemistry.
  8. European Hardware/Photonics-Heavy Pharma & Research Orgs (German firms noted by Mishra, plus EU programs like Horizon Europe) — Partnerships to modernize legacy systems with advanced label-free biosensing.
  9. Defense/Health Agencies (e.g., DARPA, DTRA) — Applications in biothreat detection, rapid countermeasure development, or soldier health monitoring via cellular-level insights.
  10. Big Tech + Life Sciences Hybrids or Cloud Providers (e.g., Google DeepMind/Verily, Amazon AWS Health, or Microsoft Research partnerships) — Co-building foundational models trained on Cell Cinema data streams, with infrastructure or enterprise licensing deals.
These are not exhaustive. Additional upside exists in academic core facilities (scaled via consortia), emerging markets in Asia, and downstream diagnostics or personalized medicine once the platform matures. A few large wins — like a NASA-style anchor contract — could cascade into the rest.
PreciGenetics does not need another incremental VC round that values it like a SaaS startup. It needs bold customers who recognize that better measurement of living biology is a prerequisite for the next wave of breakthroughs. Just as NASA bet on SpaceX to make spaceflight reliable and affordable, strategic players in health and biotech should write the checks that let PreciGenetics build at the speed the mission demands.
The technology is too important — and the opportunity too large — for slow, equity-heavy capital. The era of Cell Cinema needs customers, not just investors.



PreciGenetics Is Too Big for Venture Capital: Why Strategic Customers Paying in Advance Are the Better Path
PreciGenetics is developing Cell Cinema — a label-free, photonic-AI platform that generates real-time “chemical movies” of living cells in action. Instead of killing cells for static snapshots via traditional staining or sequencing, it enables continuous, non-destructive observation of dynamic cellular processes. This breakthrough addresses fundamental limitations in drug discovery, cell and gene therapy manufacturing, precision medicine, and beyond by producing rich, predictive datasets that modern AI can truly leverage.
This is not an incremental SaaS tool or a modest biosensor play. It is foundational infrastructure for digitizing living biology at scale — comparable in ambition to how sensors and compute revolutionized physics, aerospace, and information technology. With this scope, PreciGenetics is too big for traditional venture capital.Venture Capital Is the Wrong ModelVC funding works well for software businesses with rapid iteration, clear product-market fit, and 3–7 year exit timelines. PreciGenetics operates at the complex intersection of photonics hardware, AI, and biology, with longer development cycles, regulatory hurdles, and significant capital needs for scaling instrumentation and data infrastructure.
Raising sufficient capital through VC at this stage would likely result in substantial dilution, pressure for premature pivots toward smaller markets, or forced incrementalism that slows the core mission. Contrast this with the SpaceX model: Elon Musk’s company had effectively zero traditional VC backing for its foundational vision. Instead, NASA stepped in as a customer with massive contracts — billions in development funding and launch services. These were not equity deals. They were purchase orders and milestone-based payments that provided non-dilutive capital, technical validation, and a clear path to reliability at scale.
Large government and enterprise customers like NASA and NIH operate similarly today. They pay in advance, place substantial orders, fund development through contracts and grants, and — crucially — do not ask for equity. This structure aligns incentives around delivery and real-world impact rather than the next fundraising round. For a deep-tech biology platform like Cell Cinema, this customer-led model de-risks the technology faster and preserves founder and early-team ownership while accelerating deployment.The Power of Strategic Mega-CustomersPreciGenetics’ real-time, non-destructive cellular insights solve existential pain points: reducing failure rates in billion-dollar drug pipelines, slashing per-patient costs in cell therapies (often $400k–$500k+ total), optimizing biomanufacturing yields, and enabling predictive biology. Customers who stand to gain the most are willing and able to write large checks upfront through platform purchases, co-development agreements, service contracts, and long-term data/insight partnerships.
Here is a targeted list of 10 categories of potential customers that could collectively direct $100M+ toward PreciGenetics through advance payments, orders, and non-dilutive funding as the technology scales:
  1. Major Pharma Corporations (Pfizer, Roche, Novartis, Merck & Co.) — Multi-year platform deployments for high-throughput screening, mechanism-of-action studies, and toxicity profiling, with payments tied to installed systems and performance milestones.
  2. Cell & Gene Therapy Developers (Gilead/Kite, Bristol Myers Squibb, bluebird bio, Legend Biotech) — Integration into manufacturing suites for real-time process analytical technology (PAT), quality control, and yield improvement in CAR-T and autologous therapies.
  3. Global CDMOs (Lonza, WuXi Biologics, Catalent, Samsung Biologics) — Biosensing layers embedded in client manufacturing runs, funded via large service contracts and capacity reservations paid in advance.
  4. U.S. Biomedical Research Agencies (NIH, BARDA, ARPA-H) — Contracts and grants for foundational tools, advanced manufacturing platforms, and pandemic preparedness — characteristically paid via upfront or milestone disbursements.
  5. Regulatory & Standards Bodies (FDA collaborations or pharma consortia) — Programs to validate next-generation analytics for accelerated approvals, often supported by government or industry pooled funding.
  6. Leading Cancer & Research Hospitals (MD Anderson, Memorial Sloan Kettering, Dana-Farber, or international equivalents) — Precision oncology applications using patient-derived cells and organoids, funded through research budgets and philanthropic/government channels.
  7. Agri-Biotech & Industrial Synthetic Biology Firms (Corteva, Ginkgo Bioworks, Amyris, or similar) — Strain engineering and bioprocess optimization for microbes and plant cells, with commercial-scale orders.
  8. European Research & Photonics Ecosystems (German pharma/hardware incumbents, Horizon Europe programs, Fraunhofer institutes) — Modernization partnerships to upgrade legacy systems with advanced label-free sensing.
  9. Defense & National Security Agencies (DARPA, DTRA, or allied equivalents) — Biothreat detection, rapid countermeasure development, and health monitoring platforms, typically funded with significant upfront commitments.
  10. Big Tech Life Sciences Partnerships (Verily/Google, Amazon AWS Health, Microsoft Research, or similar) — Co-development of foundational AI models trained on Cell Cinema streams, with infrastructure deals and enterprise licensing paid as committed orders.
These customers do not just write checks — they provide anchor validation that cascades across the ecosystem. A few early wins modeled on NASA-style contracts could rapidly unlock the rest, creating a flywheel of adoption without the dilution and distraction of repeated VC rounds.The Better Capital Stack for Transformative BiologyPreciGenetics does not need another equity round that treats it like a consumer app. It needs bold customers who understand that superior measurement of living systems is the prerequisite for the next generation of medicines, therapies, and bio-economies. NASA did not take equity in SpaceX; it placed orders and paid for results. NIH, BARDA, ARPA-H, pharma giants, and CDMOs can — and should — do the same here.
Large customers pay in advance. They place real orders. They seek solutions, not ownership stakes. For a platform as consequential as Cell Cinema, that is the superior path: non-dilutive capital aligned with mission-critical outcomes.
The technology is too important, and the addressable impact too vast, to be constrained by traditional VC timelines and terms. PreciGenetics is ready for customers who will write the checks — and let the science move at the speed the world needs.


NASA Contracting Models: Non-Dilutive, Milestone-Driven Funding That Empowers Ambitious Deep-Tech Companies
NASA has pioneered flexible, performance-oriented contracting models that provide substantial non-dilutive capital to private companies without taking equity. These mechanisms de-risk high-ambition technologies while aligning payments with tangible progress—exactly the model that allowed SpaceX to scale its vision with minimal traditional VC reliance. For platforms like PreciGenetics’ Cell Cinema, analogous customer contracts from NASA-style agencies could deliver the upfront capital needed to build at mission speed. Key NASA Contracting Approaches1. Firm-Fixed-Price Contracts with Milestone Payments
NASA frequently uses firm-fixed-price structures, especially in commercial partnerships. The agency commits to a total value but pays incrementally upon successful completion of predefined technical, business, and performance milestones. This limits NASA’s exposure (no open-ended cost overruns) while giving companies predictable cash flow as they hit targets.
  • SpaceX examples: NASA awarded SpaceX multi-billion-dollar contracts for Human Landing System (HLS) development (~$2.9B base + options), Commercial Crew Transportation Capability (CCtCap), ISS resupply, and ISS deorbit vehicle ($843M). Payments are tied to milestones such as design reviews, tests, demonstrations, and operational flights.
  • Companies receive significant upfront or early payments to fund development, followed by tranche releases upon achievement. This is not equity investment—NASA pays for deliverables and services.

2. Space Act Agreements (SAAs)
These are highly flexible “other transaction” (OT)-like instruments unique to NASA. They enable partnerships outside strict Federal Acquisition Regulation (FAR) rules, allowing faster execution, shared risk, and innovative structures. SAAs were foundational in early Commercial Orbital Transportation Services (COTS) and Commercial Crew Development (CCDev) phases.
  • Funded SAAs provide NASA money to partners.
  • They supported milestone-based development with less bureaucracy than traditional contracts.
  • Transitioned to full FAR-based fixed-price contracts for later certification and operational phases to ensure rigorous safety and oversight.

3. Commercial Partnerships & Services Contracts
NASA buys services (e.g., launches, crew/cargo transport to ISS, lunar landings) on a fixed-price per-mission basis once systems are certified. This creates recurring revenue streams. Early development funding transitions into operational purchase orders.
4. Other Mechanisms
  • SBIR/STTR programs: Seed-stage non-dilutive grants/contracts for innovation, with pathways to larger Phase III sole-source contracts.
  • Progress payments and advances: Allowed under certain conditions, with high customary rates (85–100% depending on company size and program).
  • Cooperative agreements and Broad Agency Announcements (BAAs): For research and development collaboration.
Why This Model Works for “Too Big for VC” Technologies
  • Non-dilutive: No equity dilution or board seats. NASA seeks solutions and capabilities, not ownership.
  • Pay in advance / milestone-based: Provides working capital early while tying后续 payments to results. This funds hardware, testing, and iteration without forcing constant fundraising.
  • De-risking flywheel: Anchor contracts validate technology, attract talent, and unlock commercial markets.
  • Scale: Individual awards routinely reach hundreds of millions to billions—far beyond typical VC check sizes for deep tech—while preserving company autonomy.
  • Accountability: Fixed-price and milestone structures incentivize efficiency and delivery, as seen in SpaceX’s rapid progress compared to traditional cost-plus programs.
Traditional cost-plus contracts (reimbursing costs + fee) are still used for high-uncertainty legacy programs but have largely been supplemented or replaced by commercial models for new capabilities. The commercial approach has dramatically reduced costs per launch and accelerated innovation. Relevance to PreciGenetics and Cell CinemaPreciGenetics does not need VC dilution to hit its ambitious roadmap. It needs customers who can place large orders and pay via milestone-based contracts or SAAs—exactly as NASA has done for SpaceX and others. Agencies like NIH, ARPA-H, BARDA, and DARPA, along with large pharma and CDMOs, have analogous vehicles: milestone payments, cooperative agreements, and procurement contracts that deliver nine- and ten-figure funding without equity asks.
A single NASA/ARPA-H-style anchor contract for foundational biosensing tools, pandemic preparedness platforms, or advanced manufacturing could mirror the de-risking effect NASA provided SpaceX. Subsequent pharma and CDMO deployments would follow naturally.
Large strategic customers do pay in advance through structured orders. They fund development against deliverables. They prioritize outcomes over ownership. For transformative platforms like real-time Cell Cinema—essential for predictive biology, lower therapy costs, and faster discovery—this customer-led capital stack is not just viable. It is superior.
PreciGenetics is too big for VC because the mission demands capital and validation at the scale only serious customers can provide. NASA’s contracting playbook shows precisely how that path succeeds.


ARPA-H Funding Mechanisms: Flexible, Milestone-Driven, Non-Dilutive Capital for Transformative Health Technologies
The Advanced Research Projects Agency for Health (ARPA-H), established in 2022 within the U.S. Department of Health and Human Services (HHS), operates on a DARPA-inspired model to fund high-risk, high-reward biomedical and health innovations. Unlike traditional NIH grants, which are often hypothesis-driven and incremental, ARPA-H targets breakthroughs that could reach real-world impact in 5–10 years. It uses agile contracting vehicles, active program management, and milestone-based payments to accelerate progress while minimizing bureaucracy.
This structure makes ARPA-H an ideal strategic customer for deep-tech platforms like PreciGenetics’ Cell Cinema — real-time, label-free photonic-AI imaging of living cells — which could transform drug discovery, cell/gene therapy manufacturing, precision medicine, and biomanufacturing.Primary Funding MechanismsARPA-H primarily uses Other Transactions (OTs) and Cooperative Agreements for R&D, along with contracts and limited grants. It does not rely on standard NIH grant mechanisms.
  • Other Transactions (OTs): The most flexible tool. These are legally binding agreements that are not procurement contracts, grants, or cooperative agreements. They avoid many Federal Acquisition Regulation (FAR) requirements, enabling faster execution, customized terms, greater IP flexibility (Bayh-Dole does not automatically apply), and commercial-like practices. OTs are ideal for engaging non-traditional performers such as startups and industry.
  • Cooperative Agreements: Provide financial assistance with substantial involvement from ARPA-H (e.g., close collaboration with Program Managers). More structured than OTs but still allow flexibility compared to standard grants.
  • Procurement Contracts: Used when ARPA-H is acquiring specific goods/services or technology.
  • Other Tools: SBIR/STTR for small businesses, cash prizes, Broad Agency Announcements (BAAs), Innovative Solution Openings (ISOs), and targeted programs/initiatives.
Milestone-Based Payments: Pay for Performance, Not Just PromisesA core feature distinguishing ARPA-H from traditional grants (often lump-sum or cost-reimbursable upfront) is its emphasis on milestone-driven funding. Payments are tied to predefined technical, performance, and exit criteria negotiated upfront.
  • Fixed-price milestone payments: Performer receives a set amount upon successful completion of a milestone (costs incurred don’t directly affect the payment if the milestone is met). This incentivizes efficiency.
  • Expenditure-based approaches: Payments linked to actual costs with reporting, offering some flexibility.
  • Advances and progress payments: Possible, with structured tranches supporting development.
This model provides non-dilutive capital early while de-risking taxpayer funds — payments are contingent on results. It mirrors NASA’s approach with SpaceX: milestone payments for development without equity. ARPA-H Program Managers actively manage projects, with “fail fast” gates to redirect or stop underperforming efforts. How Opportunities Arise and Scale
  • Programs: Focused, multi-project efforts on specific challenges.
  • Initiatives/Sprints/ISOs: Rapid-response funding opportunities outside existing programs.
  • Process: Often starts with solution summaries or abstracts, followed by invitations for full proposals. Highly competitive, merit-based evaluation emphasizing technical merit, impact, and feasibility.
Awards can range from millions to tens of millions per project (or more for larger programs), with ARPA-H’s annual budget around $1.5B+ (FY2026 proposals/appropriations in that range). Why This Fits “Too Big for VC” Companies Like PreciGenetics
  • No equity demanded: ARPA-H funds solutions, not ownership.
  • Upfront / milestone capital: Supports hardware development, data infrastructure, and scaling without constant fundraising or dilution.
  • IP and commercialization flexibility: Especially via OTs.
  • Strategic validation: An ARPA-H award de-risks the technology for pharma, CDMOs, and other customers.
  • Alignment with Cell Cinema: Perfect for ARPA-H’s focus areas (e.g., Scalable Solutions, Health Science Futures) — advanced manufacturing, predictive biology, reducing therapy costs, pandemic preparedness, or AI-driven research platforms.
Strategic Implications for PreciGeneticsJust as NASA contracts provided SpaceX with non-dilutive, milestone-based funding to prove its vision, ARPA-H (along with BARDA, NIH mechanisms, and DARPA) offers PreciGenetics a customer-led path. A foundational award for real-time biosensing tools could fund platform maturation, generate critical data, and serve as an anchor that attracts pharma and manufacturing partners.
ARPA-H’s mechanisms prioritize speed, flexibility, and outcomes over rigid compliance or incrementalism. For foundational technologies that digitize living biology and slash failure rates in high-stakes pipelines, this is the right capital stack: bold, mission-aligned, and non-dilutive.
Large strategic customers like ARPA-H do pay in advance via structured orders and milestones. They seek transformative capability, not equity. PreciGenetics — and similar deep-tech biology platforms — should pursue these avenues aggressively to build at the speed the health challenges demand.

at No comments:
Labels: , ,
Subscribe to: Posts (Atom)